CLAIMS

1. A synthetic polynucleotide comprising
   (i) at least 21 contiguous nucleotides of SEQ ID NO: 1, and
   (ii) a double stranded region having at least 6 base pairs.
2. The synthetic polynucleotide of claim 1, wherein the double stranded region is formed by 6 or more of the 3' and 5' nucleotides at or near the termini.
3. The synthetic polynucleotide of claim 1, comprising at least one chemical modification which is made to one selected from the group consisting of the sugar, nucleobase or internucleoside linker of the synthetic polynucleotide.
4. The synthetic polynucleotide of claim 1, wherein each nucleotide comprises at least one chemical modification which is made to one selected from the group consisting of the sugar, nucleobase or internucleoside linker of the synthetic polynucleotide.
5. The synthetic polynucleotide of claim 3 or claim 4, wherein the modification is made to a sugar and the modification consists of a 2' O-Methyl modification.
6. The synthetic polynucleotide of claim 3, further comprising a 3' and/or 5' terminal cap.
7. The synthetic polynucleotide of claim 6, wherein the 3' and/or 5' terminal cap is an inverted deoxythymidine, or an amino group (NH_2).
8. The synthetic polynucleotide of claim 6, wherein the 3' terminal cap comprises an inverted deoxythymidine and the 5' terminal cap comprises an amino group (NH_2).
9. The synthetic polynucleotide of claim 8 which is SEQ ID NO: 2.
10. The synthetic polynucleotide of claim 3, further comprising a polyethylene glycol conjugate, wherein the polyethylene glycol conjugate is attached to the 5' terminus of the polynucleotide, or the 3' terminus of the polynucleotide.
11. The synthetic polynucleotide of claim 10 which is SEQ ID NO: 3.
12. A complementary synthetic polynucleotide which is capable of hybridizing with, or binds to, in whole or in part any of the synthetic polynucleotides of any of claims 1-11.
13. The complementary synthetic polynucleotide of claim 12, comprising at least 12 contiguous nucleotides of SEQ ID NO: 4.
14. The complementary synthetic polynucleotide of claim 13, wherein at least one nucleotide comprises a chemical modification.

15. The complementary synthetic polynucleotide of claim 13, wherein each of the nucleotides comprises at least one chemical modification.
16. The complementary synthetic polynucleotide of claim 14, wherein the at least one chemical modification is a 2'-O-methyl modification to a nucleotide sugar.
17. The complementary synthetic polynucleotide of claim 13, which comprises a 3' terminal cap.
18. The complementary synthetic polynucleotide of claim 17, wherein the 3' terminal cap is an inverted deoxythymidine.
19. A complementary synthetic polynucleotide comprising SEQ ID NO: 5.
20. A composition comprising a synthetic polynucleotide of any one of claims 1-19 for use as a medicament for

    (a) treatment of a disease, disorder or complication relating to Von Willebrand Factor (VWF);

    (b) treatment of a ventricular assist devices (VAD)-associated complication or disorder;

    (c) treatment of sickle cell disease;

    (d) treatment of a complication or disorder associated with gastrointestinal (GI) bleeding associated with angiodysplasia;

    (e) treatment of central nervous system (CNS) thrombosis associated with severe and/or cerebral malaria;

    (f) treatment of gastrointestinal (GI) bleeding associated with Heyde's Syndrome;

    (g) restoring vessel patency in a subject having one or more vessel(s) occluded with at least one occlusive thrombus, wherein the vessel(s) are at least 50% occluded;

    (h) disaggregating one or more occlusive thrombi in a subject having at least one vessel that is at least 50% occluded; or

    (i) preventing platelet aggregation in a subject having a thrombotic disorder or complication.
21. The composition according to claim 20, wherein, for use of (a), the disease, disorder or complication relating to VWF is a thrombotic disorder, including ischemic stroke.
22. The composition according to claim 20, wherein, for use of (b), the VAD associated complication or disorder is selected from acquired Von Willebrand Syndrome (aVWS), angiodysplasia, occlusive thrombosis, and VAD-associated pump thrombosis.
23. The composition according to claim 20, wherein, for use of (g) or (h), the external layer of the occlusive thrombi is disaggregated.

24. The composition according to claim 20, wherein, for use of (g) or (h), the occlusive thrombi are formed under conditions of shear rates that are 10,000 s^{-1} or greater.
25. The composition according to claim 20, wherein, for use of (g) or (h), the occlusive thrombi are resistant to fibrinolysis and/or antithrombotic agents.
26. The composition according to claim 20, wherein, for use of (g) or (h), the subject has a condition selected from acute coronary syndrome, acute occlusion thrombosis, and ischemic stroke.
27. The composition according to claim 20, wherein the synthetic polynucleotide is administered via intravenous injection, or subcutaneous injection.
28. The composition according to claim 27, wherein the polynucleotide is administered via intravenous injection, and wherein the polynucleotide is administered at a dose of from about 0.01 mg/kg to about 0.5 mg/kg of the subject body weight.
29. The composition according to claim 28, wherein the synthetic polynucleotide has a plasma half-life of from about 70 hours to about 100 hours.
30. The composition according to claim 20, wherein, for use of (i), the thrombotic disorder or complication is myocardial infarction, or ischemic stroke.